NCT03569553View on ClinicalTrials.gov

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 30, 2026

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Inhalational Anthrax
Interventions
DRUG

AIGIV

Anthrax Immune Globulin Intravenous (Human)

Sponsors
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY